Boehringer Ingelheim Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Pradaxa (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis and pulmonary embolism in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent deep venous thrombosis and pulmonary embolism in patients who have been previously treated. Deep venous thrombosis and pulmonary embolism are collectively referred to as venous thromboembolism.
Benjamin Starnes (Seattle, USA) told the audience attending yesterday’s mini symposium on acute aortic transection that intravascular ultrasound (IVUS) was an important tool in the management of patients with blunt aortic injury undergoing thoracic endovascular aortic repair (TEVAR) because it helps to ensure accurate sizing of the endograft and prevent rupture. The session also reviewed the differences between image-based classifications of blunt aortic injury.
The CX Great Debate saw Peter Taylor, London, UK, and Richard Gibbs, Imperial College, London, UK, persuaded 71% of the audience at the Charing Cross International Symposium yesterday to vote for their position against the motion “For uncomplicated type B dissections, early intervention is indicated”.
Michael Dake, Stanford, USA, outlined the first experiences with the Gore TAG (W L Gore) thoracic branch endoprosthesis and Frank R Arko, Charlotte, USA, presented on the MONA LSA (Medtronic) branched device results at a session yesterday. Both speakers shared early cases and their results.
At the ilegx Collaboration Day, attendees learnt about the best management therapies for diabetic foot care and vascular reconstruction in critical limb ischaemia patients and for the second year running, the symposium broadcast edited live cases treating superficial femoral artery lesions to the Far East and North America in an event named Endovascular Electronic Education, sponsored by Abbott Vascular.
A session held yesterday at the Charing Cross International Symposium revealed that there is a widespread lack of physician awareness about the dangers of radiation in the interventional suite. The effect of exposure to radiation has become particularly important with the move from open to endovascular procedures, and delegates heard how no single specialty had a monopoly on bad practice when it came to radiation.
At CX 2014, a mini symposium on abdominal compartment syndrome shed light on how little is known about the condition. It became apparent that the syndrome still has not been clearly defined, many of its triggering factors have yet to be recognised, and its management is limited to surgical decompression. Therefore, preventing both intra-abdominal hypertension and preventing intra-abdominal aortic hypertension from developing into abdominal aortic compartment syndrome is key
Giovanni Pratesi (Florence, Italy) reported that the two-year results of the INNOVATION study (A multicentre, open-label, prospective, non-randomised study of the Cordis Incraft system in subjects with abdominal aortic aneurysms) confirm the “very promising results” of the one-year outcomes of the Incraft bifurcated stent graft system (Cordis). The results, presented at the Charing Cross Symposium 2014 (5-8 April, London, UK), showed that the system was not associated with any endoleaks at two years in patients undergoing endovascular aortic aneurysm repair (EVAR).
Attendees at the CX Innovation Showcase learnt about the latest branched devices for endovascular aneurysm repair yesterday. New technologies for the vascular and endovascular treatment of lower limb, venous and carotid disease and arteriovenous access were also discussed. Stephen Greenhalgh (London, UK) and Andrew Holden (Auckland, New Zealand) were the chairmen of the session.
The first-ever presentation of 12-month data from the randomised multicentre IN.PACT SFA trial revealed that treatment with the IN.PACT Admiral drug-eluting balloon (Medtronic) was significantly superior to percutaneous transluminal angioplasty in terms of reinterventions and patency. The results were presented at the Charing Cross Symposium 2014 (5–8 April 2014, London, UK).
Andrew Holden, Auckland, New Zealand, presented data for on the developments in bioresorbable technology yesterday. He said that, as drug-eluting balloon data are limited to short and intermediate length lesions, bioresorbable stents or scaffolds are an “exciting prospect” for the future.
Andrew Bradbury (Birmingham, UK) reported that a new randomised controlled trial, BASIL 2, has been launched because there is an “urgent need” to undertake pragmatic, scientifically robust and publically-funded randomised controlled trials of endovascular interventions in patients with severe limb ischaemia.
The final, two-year data from the RENOVA trial that compared the use of the Flair stent-graft (Bard) to the use of percutaneous transluminal angioplasty for treatment of arteriovenous graft stenosis showed that stent grafts proved as safe as angioplasty and more effective.
Para controlar el colesterol y mantenerlo a raya es fundamental seguir unos hábitos de vida saludables que incluyan una alimentación variada y equilibrada y ejercicio físico diario. Juana Morillas, experta en nutrición consultada por el Instituto Flora, afirma que es fundamental cuidarnos durante todo el año. “Debemos intentar tomar 3 frutas y 2 raciones de hortalizas al día, incluir alimentos integrales, priorizar las carnes blancas y los pescados frente las carnes rojas, y el aceite de oliva, las margarinas y los frutos secos frente la mantequilla” asegura la Dra. Morillas. En el caso de las personas con hipercolesterolemia, es aconsejable combinar estos hábitos saludables con alimentos enriquecidos con esteroles y estanoles vegetales.
Un grupo de investigadores del IDIAP Jordi Gol estudia si hay relación entre el índice tobillo-brazo (la medida del índice tobillo-brazo es un elemento de detección de la enfermedad arterial periférica) y la incidencia de eventos cardiovasculares en población mayor de 49 años en España.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos